Blue pill. New treatments have helped reduce the impact of AIDS

An anti-viral drug, taken by thousands of men in Sydney and some Australian cities, has resulted in a dramatic drop in the rate of HIV infection, suggesting that the targeted preventive approach could speed up the elimination of the disease.

According to a study of the effect of Trophada pills produced by Gilead Sciences Inc. and its contribution to reducing the spread of the virus, the number of new HIV / AIDS cases among homosexuals has been reduced to almost one-third . People.

The study, published Thursday in the Lancet HIV Medical Journal, could pave the way for other countries to stem the spread of the disease using a so-called prophylaxis or pre-infection treatment, according to Bloomberg.

"The rapid decline of new HIV infections among gay and gay men is the first in the world," said Andrew Grolic, head of epidemiology and HIV prevention at Newbury University. Is the lowest since the start of HIV surveillance in 1985. "

International efforts are under way to eliminate the disease by 2030. The number of people living with AIDS has fallen to 1.8 million worldwide in 2017, compared with 3 million per year in the 1990s.

In the state of New South Wales, 102 HIV-positive men were infected in the first year of the study, compared with 149 the previous year.

More news on euronews:

"Over the past three or four years, we have seen the effectiveness of this treatment, and we are faced with the reservation of several parts of the world to fund the publication of this program because its impact is not clear. and that's what we're starting to do, "he said.

In the United States, about 180,000 people have taken this drug to participate in the preventive treatment program.

This oval blue pill is a combination of a fixed dose of tenofovir, disoproxyl and emtricitabine.The existing version of this drug, manufactured by Belan NV, Sibla LTV and Tiva Pharmaceutical Industries, has marketed it at a good price.

John Milligan, CEO of Gilead, confirmed at the Morgan Stanley International Conference on Health last month that the drug had achieved positive results and that its use in the United States had helped to reduce infection rates. HIV. He also said that decision-makers should start thinking seriously about his release and its adoption, to help reduce new infections.